Barinthus Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Barinthus Biotherapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 8% per year.
Key information
-25.6%
Earnings growth rate
154.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 8.0% |
| Return on equity | -36.3% |
| Net Margin | -386.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%
Nov 19
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?
Aug 31Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Revenue & Expenses Breakdown
How Barinthus Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15 | -58 | 41 | -7 |
| 30 Jun 24 | 0 | -64 | 28 | -3 |
| 31 Mar 24 | 0 | -71 | 34 | -3 |
| 31 Dec 23 | 1 | -73 | 40 | -3 |
| 30 Sep 23 | 7 | -77 | 47 | 34 |
| 30 Jun 23 | 13 | -55 | 35 | 20 |
| 31 Mar 23 | 30 | -15 | 15 | -1 |
| 31 Dec 22 | 45 | 5 | 6 | -1 |
| 30 Sep 22 | 38 | 11 | -4 | -2 |
| 30 Jun 22 | 32 | -1 | 8 | -4 |
| 31 Mar 22 | 15 | -33 | 27 | -4 |
| 31 Dec 21 | 0 | -51 | 25 | -4 |
| 30 Sep 21 | 1 | -46 | 23 | -3 |
| 30 Jun 21 | 4 | -41 | 23 | -4 |
| 31 Mar 21 | 4 | -29 | 11 | -4 |
| 31 Dec 20 | 5 | -18 | 10 | -3 |
| 31 Dec 19 | 7 | -21 | 3 | -3 |
Quality Earnings: BRNS is currently unprofitable.
Growing Profit Margin: BRNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BRNS is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare BRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BRNS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BRNS has a negative Return on Equity (-36.3%), as it is currently unprofitable.